Mirtazapina Sandoz Farmacéutica (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Sandoz Farmacéutica, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It treats major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Sandoz Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and related conditions. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Treatment‑resistant depression: provides an alternative mechanism when first‑line agents are ineffective. - Depression with prominent insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness: often pronounced at treatment initiation. - Increased appetite and weight gain: may be significant with prolonged use. - Dry mouth, constipation, or dizziness: typical anticholinergic‑like symptoms.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia: requires immediate medical attention. - Suicidal thoughts or behavior: especially during early therapy. - Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Hepatic dysfunction or jaundice: monitor liver enzymes if clinically indicated. - Seizures: rare but reported, particularly in predisposed individuals.

Before initiating therapy, consider the following precautions. - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight: due to potential for significant weight gain. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Caution in elderly patients: increased risk of sedation, falls, and confusion. - Avoid abrupt discontinuation: taper the dose to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system depressants (e.g., alcohol, benzodiazepines): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Antihypertensive drugs: potential for enhanced hypotensive effect. - Anticholinergic medications: additive anticholinergic burden may worsen dry mouth or constipation.